British Journal of Haematology · 2019 · 63 citations · 23 references
MedicineImmunologyOncologyCancer ImmunologyHematologic OncologyImmunogeneticsImmuno-oncology BiomarkersLymphoid NeoplasmsNext-generation Sequencing In OncologyCombination ImmunochemotherapyEzh2 FunctionLymphoma BiomarkersLymphoma Molecular ClassificationLymphoma Treatment ResponsePrognostic Index DevelopmentRandomized Clinical TrialsRituximab-based Therapy
The clinical course of follicular lymphoma (FL) is highly variable. Recently the m7-FL international prognostic index (FLIPI) integrating performance status, FLIPI score and the mutational status of seven genes, was shown to stratify patients into "low-risk" and "high-risk" with respect to 5-year failure-free survival after first-line immunochemotherapy. Our aim was to evaluate the model after rituximab without chemotherapy. The Nordic Lymphoma Group performed two randomized clinical trials on indolent lymphoma patients receiving single rituximab and rituximab with interferon-α2a. In total, 95 FL patients had sufficient fresh-frozen diagnostic material for sequencing. A targeted panel for the genes EZH2, ARID1A, MEF2B, EP300, FOXO1, CREBBP and CARD11 was utilized for m7-FLIPI score calculation. With a median follow-up of 10·6 years, 76% of patients were alive. No difference in time to treatment failure (TTF), defined as the interval between start of trial therapy and initiation of new therapy or death, nor overall survival (OS) was found between the m7-FLIPI risk groups (log-rank P = 0·94 and 0·99, respectively). EZH2 mutations were associated with longer TTF (log-rank P = 0·04) and in EP300 mutations were associated with shorter TTF (log-rank P = 0·01). We conclude that the prognostic value of the m7-FLIPI clinicogenetic model seems dependent on therapeutic regimen.
23
Follicular Lymphoma International Prognostic Index
Blood · 2004 · 1.5K citations · Full text
Medicine, Hematology, Oncology +16
Mathias Rummel, N. Niederle, Georg Maschmeyer et al. · The Lancet · 2013 · 1.5K citations
Medicine, Oncology, Pharmacology +6
VarScan: variant detection in massively parallel sequencing of individual and pooled samples
Daniel C. Koboldt, Ken Chen, Todd Wylie et al. · Bioinformatics · 2009 · 1.4K citations · Full text
Gilles Salles, John F. Seymour, Fritz Offner et al. · The Lancet · 2010 · 1.1K citations